REGENERATIVE CARE
in Wound CARE
Fidia offers medical devices designed to process patients' own
tissues with minimal manipulation in order to provide Regenerative Medicine autologous solutions
Since 1963, Fidia Farmaceutici has pioneered the clinical application of hyaluronic acid and has paved the way to a new concept and a novel medical approach: Regenerative Medicine.
Today, Regenerative Medicine, more specifically Autologous Biological Therapy, offers a promising new synergic role for hyaluronic acid, thanks to the development of new therapeutic strategies in all areas where Fidia Farmaceutici is already present, thereby enabling the company to always be a step ahead and establish new standards in medical treatment.
In this context, Fidia has patented an innovative technology for producing autologous micrografts, reinforcing its commitment to advancing the care of patients with hard-to-heal wounds.
AUTOLOGOUS SKIN MICROGRAFTS
Skin micrografts are autologous skin fragments that allow wound coverage by utilising a minimal amount of skin.
Autologous skin micrografts may provide the starting signal for faster endogenous wound healing thanks to their rich content of stem cell-like progenitor cells. They are considered a feasible therapeutic approach to improve chronic wound healing.